BLAINJECTIONINJECTABLE
Approved
Jul 2023
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
9
Data completeness
5/8 — Partial
BEYFORTUS (nirsevimab) by AstraZeneca is fusion protein inhibitors [moa]. Approved for respiratory syncytial virus anti-f protein monoclonal antibody [epc]. First approved in 2023.
Drug data last refreshed 20h ago
Mechanism of Action
Fusion Protein Inhibitors
Pharmacologic Class:
Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (9)
A Post-marketing Surveillance Study of Beyfortus (Nirsevimab) in Republic of Korea
Started Oct 2025
3,000 enrolled
Respiratory Syncytial Virus
Study of Monoclonal Antibody Nirsevimab Against Respiratory Syncytial Virus (RSV) in Participants up to 24 Months of Age in India
Started Jul 2025
110 enrolled
RSV Immunization
The Immunology and Safety of Maternal RSV Vaccination (ABRYSVO), Infant Nirsevimab (BEYFORTUS) Immunization, or Both Products
Started Sep 2024
181 enrolled
Respiratory Syncytial Virus Infection
BEYFORTUS™ (Nirsevimab) Effectiveness Against Medically-Attended RSV Events in Infants (BEAR Study)
Started Apr 2024
49,680 enrolled
Respiratory Syncytial Virus
A Study to Assess Safety, Pharmacokinetics Anti-Drug Antibody and Anti-RSV Antibody After 2 Doses of Nirsevimab
Started Jul 2023
33 enrolled
Respiratory Syncytial Virus Infections
Worked on BEYFORTUS at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.